Table of Contents

company-logo

AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People's Republic of China. The company's product pipeline includes Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA, which is in phase III clinical trails for the treatment of COVID-19; EV71-CA16 Bivalent for HFMD; and Valent Pneumococcal Conjugate and Polysaccharide vaccine for pneumococcal disease. It also offers Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine for Group B strep disease; Diphtheria, Tetanus and Pertussis and Haemophilus In¬uenzae type B, and Diphtheria, Tetanus and Acellular Pertussis, and Absorbed Tetanus for DTP; Haemophilus In¬uenzae Type B for Hib; and freeze-dried human rabies and mRNA human rabies vaccine. In addition, the company develops Human Papillomavirus 2 and 3-valent vaccine; Tetravalent Meningococcal Conjugate vaccine; Tetravalent In¬uenzae vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; live attenuated parotitis vaccine; and ACYW135 meningococcal polysaccharide vaccine. The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. AIM Vaccine Co., Ltd. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

AIM Vaccine Dividend Announcement

• AIM Vaccine does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on AIM Vaccine dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

AIM Vaccine Dividend History

AIM Vaccine Dividend Yield

AIM Vaccine current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing AIM Vaccine stock? Use our calculator to estimate your expected dividend yield:

AIM Vaccine Financial Ratios

P/E ratio-7.41
PEG ratio-0.08
P/B ratio2.52
ROE-33.30%
Payout ratio0.00%
Current ratio0.85
Quick ratio0.68
Cash Ratio0.18

AIM Vaccine Dividend FAQ

Does AIM Vaccine stock pay dividends?
AIM Vaccine does not currently pay dividends to its shareholders.
Has AIM Vaccine ever paid a dividend?
No, AIM Vaccine has no a history of paying dividends to its shareholders. AIM Vaccine is not known for its dividend payments.
Why doesn't AIM Vaccine pay dividends?
There are several potential reasons why AIM Vaccine would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will AIM Vaccine ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While AIM Vaccine has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is AIM Vaccine a dividend aristocrat?
AIM Vaccine is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is AIM Vaccine a dividend king?
AIM Vaccine is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is AIM Vaccine a dividend stock?
No, AIM Vaccine is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy AIM Vaccine stocks?
To buy AIM Vaccine you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy AIM Vaccine stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.